Table 1. Characteristics of the Patients at Baseline, Efficacy Analysis Seta.
| Characteristic | No. (%) | |
|---|---|---|
| DCVAC/PCa group (n = 787) | Placebo group (n = 395) | |
| Age, median (range) [No.], y | 68 (46-89) [787] | 69 (46-89) [395] |
| Raceb | ||
| Asian | 5 (0.6) | 4 (1.0) |
| Black or African American | 26 (3.3) | 19 (4.8) |
| Native Hawaiian or Other Pacific Islander | 1 (0.1) | 0 |
| White | 733 (93.1) | 358 (90.6) |
| Otherc | 4 (0.5) | 3 (0.8) |
| Unknown | 18 (2.3) | 11 (2.8) |
| Ethnicity | ||
| Hispanic or Latino | 22 (2.8) | 6 (1.5) |
| Not Hispanic or Latino | 763 (97.0) | 388 (98.2) |
| Unknown | 2 (0.3) | 1 (0.3) |
| Region | ||
| US | 144 (18.3) | 73 (18.5) |
| Non-US | 643 (81.7) | 322 (81.5) |
| ECOG PS | ||
| 0 | 477 (60.6) | 239 (60.5) |
| 1 | 300 (38.1) | 150 (38.0) |
| 2 | 10 (1.3) | 6 (1.5) |
| Gleason score at diagnosis | ||
| 8-10 | 431 (54.8) | 223 (56.5) |
| <8 | 341 (43.3) | 158 (40.0) |
| Unknown | 15 (1.9) | 14 (3.5) |
| Time from prostate adenocarcinoma diagnosis, median (range) [No.], y | 4.0 (0-25) [786] | 3.7 (0-32) [395] |
| Patients with measurable disease at screening | 359 (45.6) | 183 (46.3) |
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.
a
See eTable 1 in Supplement 2 for additional baseline characteristics.
b
Information was obtained from the patients’ medical records.
c
Races other than those listed were recorded as “Other.”